CoChat

Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Nivolumab is an immune checkpoint inhibitor (ICI) currently undergoing Phase III clinical trials for the treatment of glioblastoma. The authors present the case of a 10-year-old girl with glioblastoma treated with nivolumab under compassionate-use guidelines. After the first dose of nivolumab the patient developed hemiparesis, cerebral edema, and significant midline shift due to severe tumor necrosis. She was managed using intravenous dexamethasone and discharged on a dexamethasone taper. The patient's condition rapidly deteriorated after the second dose of nivolumab, demonstrating hemiplegia, seizures, and eventually unresponsiveness with a fixed and dilated left pupil. Computed tomography of her brain revealed malignant cerebral edema requiring emergency decompressive hemicraniectomy. Repeat imaging demonstrated increased size of the lesion, reflecting immune-mediated inflammation and tumor necrosis. The patient remained densely hemiplegic, but became progressively more interactive and was ultimately extubated. She resumed nivolumab several weeks later, but again her condition deteriorated with headache, vomiting, swelling at the craniectomy site, and limited right-sided facial movement following the sixth dose. MRI demonstrated severe midline shift and uncal herniation despite her craniectomy. Her condition gradually declined, and she died several days later under “do not resuscitate/do not intubate” orders. To the authors' knowledge, this represents the first case of malignant cerebral edema requiring operative intervention following nivolumab treatment for glioblastoma in a pediatric patient.

Overview

Integrity signals

Registry

Crossref · 10.3171/2016.8.peds16326

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Cited by

See all 53

Metadata

Authors
Zhu, X., McDowell, M. M., Newman, W. C., Mason, G. E., Greene, S., & Tamber, M. S.
Affiliations
  • Department of Neurological Surgery, and
  • University of Pittsburgh (US)
Corresponding author
McDowell, Michael M.
Venue
Journal of Neurosurgery: Pediatrics
Published
2017-02
Volume
19
Issue
2
Pages
249-253
ISSN
  • 1933-0707 (ISSN-L)
  • 1933-0715
OpenAlex
W2555536348
Cited by
53
References
17
Citations by year
2025: 2 · 2024: 1 · 2023: 4 · 2022: 5 · 2021: 7 · 2020: 4 · 2019: 9 · 2018: 13 · 2017: 8
FWCI
7.26
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Neurosurgery Pediatrics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
Keywords
nivolumab, pediatric glioblastoma, immune checkpoint inhibitors, immune-related adverse events, malignant cerebral edema, tumor necrosis, decompressive hemicraniectomy, midline shift, uncal herniation, hemiparesis, seizures, dexamethasone
MeSH terms
Nivolumab, Antibodies, Monoclonal, Antineoplastic Agents, Brain, Brain Edema, Brain Neoplasms, Child, Female, Glioblastoma, Humans, Fatal Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.